Table 1.
Characteristics of patients with clinically localized prostate cancer by weekly vigorous physical activity frequency in the year prior to diagnosis.
| Characteristic | Vigorous physical frequency | |||
|---|---|---|---|---|
| <1 time/week n=283 | 1–3 times/week n=713 | >3 times/week N=357 | ||
| Study | HIM | 142 (40%) | 337 (47%) | 106 (37%) |
| PROS | 215 (60%) | 376 (53%) | 177(63%) | |
| Age | Median (25%,75%) | 60 (56,65) | 59 (54,63) | 60 (56,64) |
| Race | Caucasian | 255 (90%) | 662 (93%) | 325 (91%) |
| African American | 28 (10%) | 51 (7%) | 32 (9%) | |
| Education | High school or less | 75 (27%) | 109 (15%) | 53 (15%) |
| College/vocational school | 85(30%) | 166 (23%) | 70 (20%) | |
| Bachelor degree | 55(19%) | 219(31%) | 110 (31%) | |
| Graduate school | 68(24%) | 219(32%) | 124 (35%) | |
| BMI | < 25 | 75 (27%) | 135 (30%) | 73 (37%) |
| 25.0–29.9 | 212(48%) | 367 (51%) | 134 (51%) | |
| >30 | 131(26%) | 181 (19%) | 45 (12%) | |
| Alcohol | < 1 drink/week | 64 (23%) | 137 (19%) | 65 (18%) |
| ≥1 drinks/week | 219(77%) | 576 (81%) | 292(82%) | |
| Smoking | Never | 105 (37%) | 315 (44%) | 165 (46%) |
| Former | 127 (45%) | 331 (46%) | 172 (48%) | |
| Current | 51 (18%) | 67 (10%) | 20 (6%) | |
| PSA level at diagnosis | 0–3.9 | 25(10%) | 102(15%) | 60 (18%) |
| 4–9.9 | 162 (63%) | 426 (64%) | 207(62%) | |
| 10–19.9 | 49 (19%) | 98 (15%) | 43 (13%) | |
| >20 | 22 (8%) | 41(6%) | 22 (6%) | |
| Gleason sum | 2–6 | 161(57%) | 408 (57%) | 203 (57%) |
| 3+4 | 78 (28%) | 212 (30%) | 102 (29%) | |
| 4+3 | 19 (7%) | 42(6%) | 22 (6%) | |
| 8–10 | 24 (9%) | 50(7%) | 29 (8%) | |
| Risk category (D’Amico) | Low | 106(37%) | 295(41%) | 143 (40%) |
| Intermediate | 71(25%) | 165(23%) | 90 (25%) | |
| High | 106(37%) | 253(35%) | 124(35%) | |
| Primary treatment | Radical prostatectomy | 158 (56%) | 460(65%) | 228(64%) |
| Radiation or Radiation + ADT | 87 (31%) | 181(25%) | 93 (26%) | |
| ADT | 9 (3%) | 11(2%) | 4 (1%) | |
| Other treatment | 29(10%) | 61(9%) | 32(9%) | |
| Metastatic-lethal status as of the last follow-up (Dec. 2016) | No metastatic-lethal progression | 245(87%) | 653(92%) | 327(92%) |
| Metastatic-lethal progression | 38(13%) | 60(8%) | 30(8%) | |